<article id="initiate_easipak" class="slide initiate_easipak" data-ag-name="Intitiate EasiPak">
  <h2 class="slide-title"><span class="title-icon"></span><span>Steps to initiating EasiPak<br>in your clinic 
</span></h2>

  <div id="initiate-easipak-pop-link"></div>
    
  </div>

  <div id="popup-text">
    <div class="popup-slide">
      <div class="header">
        <h3>Ultravist<sup class="reg">&reg;</sup></h3>
        <h4>An iodine based non-ionic monomeric low osmolar extracellular X-ray contrast medium (LOCM)</h4>
        <h5>Three different iodine concentrations to meet your clinical needs</h5>
      </div>
      <div class="text">
        <p><b>IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:</b> Ultravist<sup class="reg">&reg;</sup> (iopromide) is not indicated for use in myelography, cerebral ventriculography, and cisternography. Ultravist<sup class="reg">&reg;</sup> should not be administered to patients with known hypersensitivity to the drug, or with manifest hyperthyroidism.</p>
        <p><b>MOST COMMON ADVERSE REACTIONS:</b> The most frequently observed adverse drug reactions (>4%) in patients receiving Ultravist<sup class="reg">&reg;</sup> are headache, nausea, and vasodilation.</p>
        <p><b>Please consult the Product Monograph at <a href="http://www.bayer.ca/ultravist">www.bayer.ca/ultravist</a> for important information relating to adverse reactions, drug interactions and dosing information.</b></p>
        <p><b>Reference: 1.</b> Palkowitsch PK, et al. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. <i>Acta Radiol</i> 2014;55(6):707–14.</p>         
      </div>
    </div>
    <div class="popup-slide">
      <div class="header">
        <h3>Ultravist<sup class="reg">&reg;</sup></h3>
        <h4>An iodine based non-ionic monomeric low osmolar extracellular X-ray contrast medium (LOCM)</h4>
        <h5>Three different iodine concentrations to meet your clinical needs</h5>
      </div>
      <div class="text">
        <p><b>IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:</b> Ultravist<sup class="reg">&reg;</sup> (iopromide) is not indicated for use in myelography, cerebral ventriculography, and cisternography. Ultravist<sup class="reg">&reg;</sup> should not be administered to patients with known hypersensitivity to the drug, or with manifest hyperthyroidism.</p>
        <p><b>MOST COMMON ADVERSE REACTIONS:</b> The most frequently observed adverse drug reactions (>4%) in patients receiving Ultravist<sup class="reg">&reg;</sup> are headache, nausea, and vasodilation.</p>
        <p><b>Please consult the Product Monograph at <a href="http://www.bayer.ca/ultravist">www.bayer.ca/ultravist</a> for important information relating to adverse reactions, drug interactions and dosing information.</b></p>
        <p><b>Reference: 1.</b> Palkowitsch PK, et al. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. <i>Acta Radiol</i> 2014;55(6):707–14.</p>         
      </div>
    </div>
  </div>

</article>